Recent News
Trigemina, Inc. Reports Positive Results with its Lead Compound TI-001 in a Phase IIa Clinical Trial for Chronic Daily Headache
August 10, 2010, 09:45 AM
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Trigemina, Inc. (TI), a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache (CDH). The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.